# US 2023/0055382 A1 · Detecting gut barrier dysfunction and/or cirrhosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055382 A1
- Document ID: US20230055382A1
- Status: Published application
- Kind: A1
- Application number: 17/794,750
- Filed: 2021-01-22
- Published: 2023-02-23
- Earliest claimed: 2020-01-24
- Applicants: Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Inventors: David Anderson; Huy Van; Jessica Howell
- Web page: https://patentgrep.com/patent/US20230055382A1

## CPC

- C07K 16/42: against immunoglobulins
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/54388: {based on lateral flow}
- G01N 33/6854: {Immunoglobulins}
- G01N 2800/06: Gastro-intestinal diseases
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods, kits and a test strip for detecting gut barrier dysfunction and/or cirrhosis in a subject. In addition, a method of treating a subject with gut barrier dysfunction and/or cirrhosis is provided.

## Claims

### Claim 1

A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA level and mIgA level in a biological sample from the subject and a ratio thereof and comparing the ratio to a threshold.

### Claim 2

A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA1 or dIgA2 level and mIgA1 or mIgA2 level in a biological sample from the subject and a ratio thereof and comparing the ratio to a threshold.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein a difference from the threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein an elevated dIgA to mIgA ratio or elevated dIgA1 to mIgA1 ratio or elevated dIgA2 to mIgA2 ratio compared to a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein a decreased mIgA to dIgA ratio or decreased mIgA1 to dIgA1 ratio or decreased mIgA2 to dIgA2 ratio compared to a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 6 (depends on 1, 3, 4)

The method of any one of claim 1, 3 or 4, wherein a dIgA to mIgA ratio greater than or equal to a threshold of 0.65 indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 7 (depends on 1, 3, 4)

The method of any one of claim 1, 3 or 4, wherein a dIgA to mIgA ratio greater than or equal to a threshold of 1 indicates gut barrier dysfunction and/or cirrhosis in a subject with HIV, or wherein a dIgA to mIgA ratio greater than or equal to a threshold of 0.5 indicates gut barrier dysfunction and/or cirrhosis in a subject with hepatitis B.

### Claim 8 (depends on 1, 3, 5)

The method of any one of claim 1, 3 or 5, wherein a mIgA to dIgA ratio of less than or equal to a threshold of 1.54 indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 9 (depends on 1, 3, 5)

The method of any one of claim 1, 3 or 5, wherein a mIgA to dIgA ratio less than or equal to a threshold of 1 indicates gut barrier dysfunction and/or cirrhosis in a subject with HIV, or wherein a dIgA to mIgA ratio equal to or less than a threshold of 2 indicates gut barrier dysfunction and/or cirrhosis in a subject with hepatitis B.

### Claim 10 (depends on 1, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 or 3 to 9, wherein the dIgA level in the sample is determined by contacting the sample with a pIgR, an anti-dIgA antibody or an anti-IgA J chain antibody and forming a detectable dIgA complex.

### Claim 11 (depends on 10)

The method of claim 10, wherein the pIgR is chimeric secretory component.

### Claim 12 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 or 3 to 11, wherein the mIgA level in the sample is determined by contacting the sample with an anti-mIgA antibody and forming a detectable mIgA complex.

### Claim 13 (depends on 2, 3, 4, 5)

The method of any one of claims 2 to 5, wherein the mIgA1 level in the sample is determined by contacting the sample with an anti-mIgA1 antibody and forming a detectable mIgA complex.

### Claim 14 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 or 3 to 11, wherein the mIgA level is determined in a sample depleted of dIgA, and IgA2 and is determined by contacting the sample with Protein L or an anti-IgA and forming a detectable mIgA complex.

### Claim 15 (depends on 2, 3, 4, 5, 13)

The method of any one of claim 2 to 5 or 13, wherein the mIgA1 level is determined in a sample depleted of dIgA, and IgA2 and is determined by contacting the sample with Protein L or an anti-IgA and forming a detectable mIgA complex.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15, further comprising determining the level of IgA2 in the sample, wherein one or both of (i) and (ii) indicates gut barrier dysfunction and/or cirrhosis in the subject:
(i) an elevated dIgA to mIgA ratio compared to a threshold; a decreased mIgA to dIgA ratio compared to a threshold; an elevated dIgA1 to mIgA1 ratio compared to a threshold; a decreased mIgA1 to dIgA1 ratio compared to a threshold; an elevated dIgA2 to mIgA2 ratio compared to a threshold; a decreased mIgA2 to dIgA2 ratio compared to a threshold, and
(ii) an elevated IgA2 level compared to a threshold.

### Claim 17 (depends on 16)

The method of claim 16, wherein an IgA2 level of greater than or equal to a threshold of 3500 DA indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 18 (depends on 16, 17)

The method of claim 16 or claim 17, wherein the IgA2 level in the sample is determined by contacting the sample with an anti-IgA2 antibody and forming a detectable IgA2 complex.

### Claim 19 (depends on 1)

The method of any one of claims 1, or 2 to 18, wherein the method comprises contacting the sample with a pIgR, an anti-dIgA antibody, or anti-IgA J chain antibody and forming a detectable dIgA complex, followed by contacting the sample with Protein L, an anti-IgA antibody or an anti-mIgA antibody and forming a detectable mIgA complex.

### Claim 20 (depends on 1)

The method of any one of claims 1, or 2 to 19, wherein the method comprises contacting the sample with a pIgR, an anti-dIgA antibody, or anti-IgA J chain antibody and forming a detectable dIgA complex, followed by contacting the sample with an anti-IgA2 antibody and forming a detectable IgA2 complex, followed by contacting the sample with Protein L, an anti-IgA antibody or an anti-mIgA antibody and forming a detectable mIgA complex.

### Claim 21 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 10 to 20, wherein one or more of the mIgA complex, dIgA complex, and IgA2 complex is detected by a reagent that binds IgA.

### Claim 22 (depends on 21)

The method of claim 21, wherein the reagent that binds IgA is selected from one or more of: anti-human IgA colloidal gold, anti-human IgA1 colloidal gold and anti-human IgA2 colloidal gold.

### Claim 23 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 10 to 22, wherein the detectable complex comprises one or more of: colloidal gold, a magnetic agent, coloured latex, carboxycellulose, carbon nanoparticles and a fluorescent label.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1 to 23, wherein the biological sample is selected from whole blood, plasma, serum or gingivo creviscular fluid.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 to 24, wherein the cirrhosis is the result of: alcohol, NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), viral hepatitis, HIV, cryptogenic, primary biliary cirrhosis, and/or primary sclerosing cholangitis.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1 to 25, wherein the cirrhosis has a Child-Pugh score of A, a Child-Pugh score of B or a Child-Pugh score of C.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1 to 26, wherein the method has a diagnostic sensitivity of at least 80% for cirrhosis.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1 to 27, wherein the method has a diagnostic specificity of at least 85% for cirrhosis.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1 to 28, wherein when the level of IgA2 is not determined, the method has one or more of:
i) a diagnostic sensitivity of at least 54% for cirrhosis with a Child-Pugh score of A;
ii) a diagnostic sensitivity of at least 69% for cirrhosis with a Child-Pugh score of B; and
iii) a diagnostic sensitivity of at least 87% for cirrhosis with a Child-Pugh score of C.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1 to 29, wherein when the level of IgA2 is determined, the method has one or more of:
i) a diagnostic sensitivity of at least 72% for cirrhosis with a Child-Pugh score of A;
ii) a diagnostic sensitivity of at least 76% for cirrhosis with a Child-Pugh score of B; and
iii) a diagnostic sensitivity of at least 88% for cirrhosis with a Child-Pugh score of C.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein for cirrhosis with a Child-Pugh score of A the method has one or more of:
i) a diagnostic sensitivity of at least 90% for alcoholic cirrhosis;
ii) a diagnostic sensitivity of at least 70% for cryptogenic cirrhosis;
iii) a diagnostic sensitivity of at least 40% for hepatitis B cirrhosis;
iv) a diagnostic sensitivity of at least 76% for hepatitis C cirrhosis;
v) a diagnostic sensitivity of at least 90% for NASH cirrhosis;
vi) a diagnostic sensitivity of at least 90% for PBC; and
vii) a diagnostic sensitivity of at least 90% for PSC.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1 to 31, wherein the method is suitable for use in a point-of-care (POC) device.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, wherein the method comprises: a chromatographic assay, enzyme-linked immunosorbent assay, fluorescent immunosorbent assay, radiological immunosorbent assay or a homogeneous assay.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1 to 33, wherein the method comprises a lateral flow format.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1 to 34, performed on a lateral flow device comprising a test strip comprising at least one sample loading region, wherein:
a) the strip comprises a capture portion comprising an agent which binds dIgA, and
b) the strip comprises a capture portion comprising an agent which binds mIgA, wherein a) is closer to the sample loading region than b) such that the sample contacts a) before b).

### Claim 36 (depends on 35)

The method of claim 35, which further comprises, between a) and b), is c) a third section of the substrate comprising an agent which binds IgA2.

### Claim 37 (depends on 35, 36)

The method of claim 35 or claim 36 which comprises flowing the sample through the device and simultaneously or subsequently flowing a detection reagent which binds IgA through the device, and detecting the detection reagent bound to IgA.

### Claim 38 (depends on 37)

The method of claim 37, wherein the detection reagent is selected from one or more of: anti-human IgA colloidal gold, anti-human IgA1 colloidal gold and anti-human IgA2 colloidal gold.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1 to 38, wherein the subject is a mammal.

### Claim 40 (depends on 39)

The method of claim 39, wherein the mammal is a human.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1 to 40, wherein the subject has a normal level of alanine aminotransferase 1 (ALT-1) and/or alanine aminotransferase.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1 to 41, wherein the method is used to monitor the progression of cirrhosis in the subject.

### Claim 43

A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the level of IgA2 in a biological sample from the subject, wherein an elevated level of IgA2 compared to a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 44 (depends on 43)

The method of claim 43, wherein a IgA2 level greater than or equal to a threshold of 3500 DA indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 45

A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the level of dIgA2 in a biological sample from the subject, wherein a level of dIgA2 that differs from a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 56, 57)

A method of treating gut barrier dysfunction and/or cirrhosis in a subject, the method comprising administering the subject a treatment for gut barrier dysfunction and/or cirrhosis, wherein the subject was determined to have a gut barrier dysfunction and/or cirrhosis using a method according to any one of claims 1 to 45 or 56 to 57.

### Claim 47

A kit for detecting gut barrier dysfunction and/or cirrhosis in a subject comprising:
(i) an agent which binds dIgA and forms a detectable dIgA complex,
(ii) an agent which binds mIgA and forms a detectable mIgA complex, wherein (i) binds specifically with dIgA and/or (ii) binds specifically with mIgA.

### Claim 48 (depends on 47)

The kit of claim 47, further comprising an agent which binds and forms a detectable IgA2 complex.

### Claim 49 (depends on 47, 48)

The kit of claim 47 or claim 48, further comprising a reagent which detects one or more of the mIgA complex, dIgA complex, and IgA2 complex.

### Claim 50 (depends on 49)

The kit of claim 49, wherein the reagent is anti-human IgA colloidal gold.

### Claim 51

The kit of any one of clams 47 to 50, wherein one or more of the agents is bound to a solid support.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The kit of any one of claims 47 to 51, wherein the kit comprises a strip, chip or cartridge for use in a lateral flow assay.

### Claim 53 (depends on 47, 48, 49, 50, 51, 52)

The kit of any one of claims 47 to 52, wherein the kit comprises a strip, chip or cartridge for use on point-of care device.

### Claim 54

A test strip for a lateral flow device comprising at least one sample loading region, wherein
a) the strip comprises a capture portion comprising an agent which binds dIgA, and
b) the strip comprises a capture portion comprising an agent which binds mIgA, wherein a) is closer to the sample loading region than b) such that the sample contacts a) before.

### Claim 55 (depends on 54)

The test strip of claim 54, wherein the strip further comprising, between a) and b), is c) a capture portion comprising an agent which binds IgA2.

### Claim 56

A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA level and mIgA level in a biological sample from the subject
wherein when the mIgA level is elevated relative to a threshold, then the dIgA level is compared to a dIgA threshold wherein a difference from the dIgA threshold indicates gut barrier dysfunction and/or cirrhosis in the subject, and
wherein when the mIgA level is decreased relative to a threshold, the ratio of the dIgA level and mIgA level is determined and compared to a ratio threshold, wherein a difference from the ratio threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.
